TW202228730A - 用於治療病毒感染的化合物及方法 - Google Patents

用於治療病毒感染的化合物及方法 Download PDF

Info

Publication number
TW202228730A
TW202228730A TW110132929A TW110132929A TW202228730A TW 202228730 A TW202228730 A TW 202228730A TW 110132929 A TW110132929 A TW 110132929A TW 110132929 A TW110132929 A TW 110132929A TW 202228730 A TW202228730 A TW 202228730A
Authority
TW
Taiwan
Prior art keywords
acetylglucosamine
derivative
vitamin
infection
medicament
Prior art date
Application number
TW110132929A
Other languages
English (en)
Chinese (zh)
Inventor
艾米爾 E 哈森
約瑟夫 哈桑 艾瑪德 卡利里
Original Assignee
艾米爾 E 哈森
約瑟夫 哈桑 艾瑪德 卡利里
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 艾米爾 E 哈森, 約瑟夫 哈桑 艾瑪德 卡利里 filed Critical 艾米爾 E 哈森
Publication of TW202228730A publication Critical patent/TW202228730A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW110132929A 2020-09-04 2021-09-03 用於治療病毒感染的化合物及方法 TW202228730A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063074602P 2020-09-04 2020-09-04
US63/074,602 2020-09-04
US202163142669P 2021-01-28 2021-01-28
US63/142,669 2021-01-28

Publications (1)

Publication Number Publication Date
TW202228730A true TW202228730A (zh) 2022-08-01

Family

ID=80491477

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110132929A TW202228730A (zh) 2020-09-04 2021-09-03 用於治療病毒感染的化合物及方法

Country Status (7)

Country Link
US (1) US20230346816A1 (cg-RX-API-DMAC10.html)
EP (1) EP4208137A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023541007A (cg-RX-API-DMAC10.html)
CA (1) CA3194024A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023002667A (cg-RX-API-DMAC10.html)
TW (1) TW202228730A (cg-RX-API-DMAC10.html)
WO (1) WO2022051575A2 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202239417A (zh) * 2021-01-29 2022-10-16 艾米爾 E 哈森 預防病毒感染之方法
US20260191887A1 (en) * 2022-04-21 2026-07-09 Therapeutikos, Inc. Methods of treating inflammation
GB2628963A (en) * 2023-02-08 2024-10-16 Univ Of Lincoln Formulations and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1533776A (zh) * 2003-03-27 2004-10-06 中国人民解放军第三军医大学 N-乙酰氨基葡萄糖在制备用于治疗病毒或细菌感染所致的局部损伤和全身症状的药物中的应用
CA2608651A1 (en) * 2005-05-24 2006-11-30 Wellgen, Inc. Compositions and methods for the prevention and treatment of conditions associated with inflammation
JP5522640B2 (ja) * 2009-10-15 2014-06-18 独立行政法人産業技術総合研究所 シアリルラクトサミン系、シアリルルイスx系のシアル酸とフコース含有新規糖鎖化合物
JP5807895B2 (ja) * 2011-02-17 2015-11-10 学校法人慶應義塾 Hcvrna複製抑制剤
EP2696680B1 (en) * 2011-04-15 2018-11-28 Marine Polymer Technologies, Inc. Treatment of hsv infections with poly-n-acetyl glucosamine nanofibers
CN107281199A (zh) * 2017-07-27 2017-10-24 吉林省始祖生物波医学研究院有限公司 N‑乙酰‑d‑氨基葡萄糖及其药物可接受盐在制备治疗病毒性肝炎药物中的应用及药物

Also Published As

Publication number Publication date
US20230346816A1 (en) 2023-11-02
WO2022051575A3 (en) 2022-04-07
MX2023002667A (es) 2023-05-12
EP4208137A4 (en) 2024-08-28
CA3194024A1 (en) 2022-03-10
WO2022051575A2 (en) 2022-03-10
EP4208137A2 (en) 2023-07-12
JP2023541007A (ja) 2023-09-27

Similar Documents

Publication Publication Date Title
Centers for Disease Control and Prevention (CDC Hospitalized patients with novel influenza A (H1N1) virus infection--California, April-May, 2009.
JP2024020274A (ja) SARS-CoV-2感染の治療における置換アミノプロピオン酸化合物の使用
US20230346816A1 (en) Compounds and methods for treating viral infection
US11491137B2 (en) Methods of improving renal function
US20230131929A1 (en) Quinoline compounds for treating respiratory disorders and viral infections
US20230094776A1 (en) Methods and compounds for the treatment or prevention of hypercytokinemia and severe influenza
TW202139987A (zh) 維多氟地莫司(Vidofludimus)用於治療或預防病毒性疾病
JP6313414B2 (ja) 外傷性傷害の処置におけるレボセチリジン及びモンテルカストの使用
JP2024511141A (ja) オリスミラストによる化膿性汗腺炎の治療
US20240325386A1 (en) Therapeutic agent for covid-19
CN112694463B (zh) 一种异戊烯基色原酮类化合物在制备抗冠状病毒药物中的用途
WO2022148403A1 (zh) 靶向il-17c的抑制剂在治疗炎症相关慢性肾脏疾病中的用途
EP4129291A1 (en) Coronavirus infection treatment drug
Matsumoto et al. A pediatric patient with interstitial pneumonia due to enterovirus D68
US20220304979A1 (en) Methods of reducing disease flares
WO2023034718A1 (en) Treatment of lower respiratory tract infection with tradipitant
EA034885B1 (ru) Новая схема лечения тиакумициновым соединением
TW202239417A (zh) 預防病毒感染之方法
RU2242222C1 (ru) Способ лечения очагового и инфильтративного туберкулеза легких
Li et al. Genetic association of COVID-19 severe versus non-severe cases by RNA sequencing in patients hospitalised in Hong Kong
JP2010111581A (ja) ドーパミンd2様受容体アゴニストを有効成分とする医薬及びスクリーニング方法
WO2025033134A1 (ja) 炎症性サイトカイン発現抑制剤及び炎症性サイトカイン発現を抑制する方法
WO2006090927A1 (ja) スルホンアミド化合物の摂食亢進作用
HK40039903B (en) Heterocyclic p38 mapk inhibitor for use in the treatment or prevention of hypercytokinemia associated with severe influenza virus infection
TW202404611A (zh) 治療發炎之方法